drugset / Trial / NCT02528019
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
RandomizedParallel-groupOpen-labelTreatment
Summary
Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes. However, how DPP-4 inhibitors or SGLT2 inhibitors exert protective actions for diabetic complications in addition to their glucose-lowering effects remains unknown.
Timeline
- Start
- 2015-08
- Primary completion
- 2017-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alogliptin | Unknown | 12.5 mg | — |
| Comparator | Alogliptin | Unknown | 25 mg | — |
| Comparator | Anagliptin | Small molecule | 100 mg | — |
| Comparator | Anagliptin | Small molecule | 200 mg | — |
| Comparator | CANAGLIFLOZIN ANHYDROUS | Small molecule | 100 mg | — |
| Comparator | Dapagliflozin | Small molecule | 5 mg | — |
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Empagliflozin | Small molecule | 10 mg | — |
| Comparator | Empagliflozin | Small molecule | 25 mg | — |
| Comparator | Glimepiride | Small molecule | 0.5 mg | — |
| Comparator | Glimepiride | Small molecule | 8 mg | — |
| Comparator | Linagliptin | Small molecule | 2.5 mg | — |
| Comparator | Linagliptin | Small molecule | 5 mg | — |
| Comparator | Luseogliflozin | Small molecule | 2.5 mg | — |
| Comparator | Luseogliflozin | Small molecule | 5 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 2.5 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | — |
| Comparator | Sitagliptin | Small molecule | 25 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |
| Comparator | TOFOGLIFLOZIN ANHYDROUS | Other / unclassified | 20 mg | — |
| Comparator | Teneligliptin | Small molecule | 20 mg | — |
| Comparator | Teneligliptin | Small molecule | 40 mg | — |
| Comparator | Trelagliptin | Small molecule | 50 mg | — |
| Comparator | Trelagliptin | Small molecule | 100 mg | — |
| Comparator | Vildagliptin | Other / unclassified | 50 mg | — |
| Comparator | Vildagliptin | Other / unclassified | 100 mg | — |
| Comparator | ipragliflozin | Small molecule | 50 mg | — |
| Comparator | ipragliflozin | Small molecule | 100 mg | — |
Indications
No indication recorded.